ANI Pharmaceuticals (ANIP)
(Real Time Quote from BATS)
$61.72 USD
-0.47 (-0.76%)
Updated Jul 22, 2024 12:32 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
Price, Consensus and EPS Surprise
ANIP 61.72 -0.47(-0.76%)
Will ANIP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ANIP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ANIP
Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data
TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids
ANIP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bayer (BAYRY) Meets Primary Goal in Nubeqa Expanded-Use Study
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why
Other News for ANIP
ANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral Powder
ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Buy Rating Affirmed: Strategic Acquisition Poised to Boost ANI Pharmaceuticals’ Revenue and Market Presence
ANI Pharmaceuticals price target raised by $7 at H.C. Wainwright, here's why